Biocon Limited — Important, 15-05-2025: General Updates

Biocon Pharma has secured US FDA approval for its Rivaroxaban Tablets USP in multiple strengths, expanding its anticoagulant portfolio. This enhances Biocon’s position in the US generics market, targeting treatments for deep vein thrombosis, pulmonary embolism, and stroke prevention in atrial fibrillation patients, potentially driving revenue growth in a high-demand therapy area.